Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study. Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Popat, Sanjay; Grosso, Federica; Steele, Nicola; Nowak, Anna K.; Novello, Silvia; Greillier, Laurent; Reck, Martin; John, Tom; Taylor, Paul; Leighl, Natasha B.; Ceresoli, Giovanni Luca; Sorensen, Jens Benn; Pavlakis, Nick; Planchard, David; Hughes, Brett Gordon Maxwell; Mazieres, Julien; Socinski, Mark A.; Buchner, Hannes; Barrueco, Jose; Scagliotti, Giorgio V.

authors

Publication Date

  • May 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 15